|Bid||210.00 x 900|
|Ask||221.77 x 800|
|Day's Range||215.41 - 224.06|
|52 Week Range||158.38 - 245.48|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||21.90|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||243.11|
United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.
United Therapeutics (UTHR) delivered earnings and revenue surprises of -41.22% and 0.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 03, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.